Tag Archives: UK

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment

The British Medical Journal's Statin 'Apology'

By Philip Ward. For any Brit involved in medical publishing, the British Medical Journal (BMJ) is the Holy Grail. So it came as a huge shock when editor-in-chief Fiona Godlee, MD, admitted last week that important — and seemingly quite basic — mistakes were made in a key paper on statins. Worse still, she didn’t […]
Posted in Europe, Guest Blog, healthcare, Medical Education, Op-Ed | Also tagged , , , , | Leave a comment

The United Kingdom: Rx for America's Pharma Tax Blues?

by Tom Norton The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing… From the US side, the most frequent thing that I have heard over the last 48 hours is, “You have got to be […]
Posted in Corporate Responsibility, Deals, Europe, FDA, Global, Guest Blog, leadership, Legal, People, Strategy | Also tagged , , , , , , , | 1 Comment

Pfizer’s AZ Bid Draws Mixed UK Reaction

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK. Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for the UK workforce”, adding that it is “absolutely crucial” that there should be “guarantees of no jobs losses and for the protection on the UK’s […]
Posted in Deals, Europe, Global, Supply Chain | Also tagged , , | Leave a comment

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta